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Answers: 
 
Question 1. CT images show multiple, expansible osteolytic lesions involving the mandible and 
maxilla, with variability in size. The largest involving the body of the left mandible measuring 
3.7 x 37.7 x 31.9 cm with cortical expansion, erosions, and multiple loculations. No peri-osteal 
reaction and no definite associated soft tissue masses.  
 
 
Question 2. Brown tumor of the mandible due to secondary hyperparathyroidism (SHPT) 
 
 
Question 3.  The management of brown tumor depends on the severity of the lesion. Control of 
hyperparathyroidism is critical as normalization of parathyroid hormone (PTH) levels will 
typically lead to the regression of tumor size or even its resolution. Surgical resection might be 
indicated for large, disfiguring tumors which fail to regress by medical treatment.  
Parathyroidectomy as well as renal transplantation could resolve the tumor.  
 
Question 4. Cinacalcet is a calcimimetic that targets the calcium sensing receptors on the 
parathyroid cells, thereby down regulating PTH levels and subsequently serum calcium and 
phosphate levels in renal failure. It significantly reduces PTH levels in patients with SHPT on 
dialysis and could help in regression of the tumor. 
 
 
 
 
 
 
 
 
 Discussion: 
 
We present a case of Brown tumor in young child originating from the cranio-facial bones 
associated with refractory SHPT. Chronic kidney disease (CKD) is associated with a disturbance 
of mineral and bone homeostasis. This condition is termed CKD-mineral bone disorder (CKD-
MBD) and represents an obstacle to optimal bone strength, final adult height, and cardiovascular 
health (1).  Impaired renal function with progressive glomerular filtration rate (GFR) reduction 
stimulates a number of compensatory mechanisms, including the increase of bone fibroblast 
growth factor-23 (FGF-23) FGF23 binds to its receptor FGFR1 and co-receptor Klotho in the 
kidney, with a key consequence in CKD being reduced 1-hydroxylase activity, resulting in 
decreased circulating 1,25 (OH)2 D with consequent SHPT) (2). High-turnover renal 
osteodystrophy and osteitis fibrosa cystica are the consequences of these changes (3). 
 
Chronic hyperparathyroidism increases bone remodeling leading to rapid osteoclastic activity, 
erosive bony lesions and peritrabecular fibrosis which can result in a local destructive 
phenomenon called Brown tumor(4). Bone pain and fractures are common complications (5, 6). 
Brown tumors can be located in any part of the skeleton, but are most frequently encountered in 
the ribs, clavicles, extremities, and pelvic girdle. Clinically significant lesions in the craniofacial 
or orbital bones are rare (7,8,9). Costal lesions are more frequent than spinal lesions (6).  It can 
also be multifocal (6). It has also been reported in children on prolonged hemodialysis (10, 11). 
A brief review of published pediatric cases is summarized in Table 1.  
 
The diagnosis of Brown tumor is established through medical history, clinical examination, 
laboratory findings and radiological imaging. Borzych et al, reported that at least one in six 
children on chronic dialysis show radiological and/or clinical signs of bone disease and 44% 
developed severe secondary HPT with PTH levels five times above the upper limit of normal, 
with a 10% higher likelihood of developing severe HPT for each year on dialysis (12). 
This fits with our case who had been on long-term dialysis for 7 years, increasing the risk of 
complications associated with end stage kidney disease (ESKD), including CKD-MBD and 
Brown tumor. Our patient had persistent hyperphosphatemia and poor metabolic control despite 
his regular hemodialysis. Compliance with medications was thought to be inconsistent. 
Potentially, more frequent and/or prolonged dialysis would have prevented or ameliorated the 
complications. Cinacalcet was added to his medications at 10-years of age, without significant 
reponse, again potentially reflecting poor compliance or refractory SHPT. Cincalcet is a 
calcimimetic that down regulates PTH levels and subsequently serum calcium and phosphate 
levels in patients with SHPT on dialysis (13). Treatment with cincalcet for nine months showed 
evidence of revision of high bone turn-over bone disease towards normal in the majority of 
patients, based on histomorphometry (2), However its use in children is not approved by the Food 
and Drug Administration (FDA). Pediatric clinical trials are on hold following the death of a 14-
year-old patient in February 2013 (14).  
 
Parathyroidectomy (PTX) is another potential treatment option in severe renal HPT refractory to 
medical treatment. Hypoparathyroidism is a potential complication after extended PTX. 
Supplementation with calcium and activated vitamin D is needed in these patients to prevent 
hypocalcaemia with all its clinical manifestations, such as seizures, tetany and arrhythmia. 
Symptomatic hypocalcaemia is most likely occur in patients with poor compliance with 
medications. PTX needs to be carefully considered in each individual patient. Timing and extent 
of parathyroidectomy require an interdisciplinary approach from both nephrologist and 
endocrine surgeons (15). 
 
One potentially overlooked contributor to CKD-MBD is metabolic acidosis as it results in bone 
demineralization and release of sodium, potassium and calcium. Furthermore metabolic acidosis 
stimulates osteoclasts and suppresses osteoblasts activity leading to direct dissolution of bone 
(16). Graham et al concluded that correction of metabolic acidosis increases the sensitivity of 
parathyroid gland to the ionized calcium leading to its suppression (17).   
 
Normalizing PTH level with medications, dialysis, parathyroidectomy, or kidney transplantation 
will often lead to tumor regression or resolution (4). Surgical resection of a Brown tumor should 
only be considered if the patient needs quick resolution if it is compromising body functions or 
promoting facial deformation (18).  
 
The management of CKD-MBD remains a challenge in children with ESKD. Our case 
demonstrates the importance of meticulous attention to markers of CKD-MBD, their correction 
with medications and/or intensified dialysis and, ideally, early renal transplantation to prevent 
such serious complications. 
 
 
First 
Author 
Age, 
years 
Gender 
(M/F) 
HD 
Duration, 
years 
Location PTH 
(pmol/L) 
Treatment Responce 
Youssef 
2016 (11) 
13 - 4 mandible 602 Complete surgical 
excision 
- 
 
 
Szeverényi_  
2011 (19) 
9 M Presented 
late 
Vertebrae 
(C1-T2) 
188.5 Complete surgical 
excision 
PTH level 
remained high 
Karabekmez 
2008 (20) 
11 M 4 Maxilla 
& 
mandible 
2,528 None Died before 
surgery 
Tarrass 
2008 (8) 
18 M 6 Mandible 1,335 Subtotal 
parathyroidectomy 
Significant 
reduction in the 
tumor size 
(Table 1): A brief review of published pediatric Brown Tumor cases 
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